Skip to main content
main-content

Oncology

Latest articles

22-09-2020 | Oncology | News | Article

NSCLC CNS recurrence significantly reduced with adjuvant osimertinib

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

21-09-2020 | Oncology | News | Article

Postoperative RT ‘not recommended’ for resected advanced NSCLC

Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.

21-09-2020 | Oncology | News | Article

Nivolumab–cabozantinib ‘a potential first-line option’ for advanced RCC

The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.

21-09-2020 | Prostate cancer | Video

ESMO 2020 | Addition of ipatasertib to abiraterone benefits certain patients with metastatic CRPC

Christopher Sweeney reports on the IPATential150 trial demonstrating the potential of combining the AKT inhibitor ipatasertib with abiraterone in metastatic castration-resistant prostate cancer patients with PTEN loss.

21-09-2020 | Breast cancer | Video

ESMO 2020 | Neoadjuvant atezolizumab plus chemotherapy supported for early TNBC

Nadia Harbeck presents the IMpassion031 study showing improved pathological complete responses with the addition of atezolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer.

20-09-2020 | Oncology | News | Article

Sacituzumab govitecan demonstrates ‘significant activity’ against heavily pretreated mUC

Further findings from the TROPHY-U-01 trial indicate that the Trop-2-directed antibody–drug conjugate sacituzumab govitecan has efficacy in heavily pretreated patients with metastatic urothelial cancer.

Image Credits